bladder disorder

Most canine bladder disorders, however, are not caused by a nervous system malfunction.

Interstitial cystitis (IC) is a chronic bladder disorder also known as painful bladder syndrome and frequency-urgency-dysuria syndrome.

Messing and Stamey reported on the presence of diffuse "mucosal glomerulations" seen with this early IC form, and they came to be known as the endoscopic hallmark of this bladder disorder (Messing & Stamey, 1978; Ratner et al., 1992).

The four adverse pediatric events associated with oxybutynin included psychiatric reactions (depression, hallucination, aggression, panic, and anger), acidosis, osmolality decrease, and bladder disorder. They occurred in patients aged 2-11 years old, said Dr.

The Feline Health Center at Cornell notes similarities between feline idiopathic cystitis (FIC)--the most common diagnosis in cats with lower urinary tract signs--and a bladder disorder affecting humans called interstitial cystitis.

Dry food tends to be dehydrating--and that's the last thing that a cat with this bladder disorder needs.

Until proven otherwise, all children with bladder disorders are constipated, (9) hence the necessity for prompt and aggressive bowel management in these patients.

Thus the present study reveals the Artemisia vulgaris and Aspslathus linaeris medicinal usefulness in hyperactive bladder disorders

Evidence for bladder urothelial pathophysiology in functional bladder disorders. BioMed Research International.

Washington, June 17 ( ANI ): A prospective study of 23 women aged 21 - 71 showed pelvic neuromodulation for bladder disorders also increased five of six sexual function scores in a validated questionnaire administered pre- and post-treatment.

Additionally, he will treat kidney and bladder disorders, incontinence andcancers of the urinary tract, and perform a variety of in-office procedures such as vasectomy and cystoscopy.

Overcoming Bladder Disorders: Compassionate, Authoritative Medical And Self-Help Solutions For Incontinence, Cystitis,

LUTS are experienced by individuals with pathology affecting the lower urinary systemarising from detrusor overactivity, sphincteric weakness, sensory bladder disorders and prostate enlargement, and are generally divided into three groups: storage, voiding and postmicturition symptoms [1].

From 2002 to 2004, he was president and CEO of Solace Therapeutics, a Framingham, Mass.-based emerging medical device company that develops and commercializes office-based treatments for bladder disorders. He also served as president and CEO of Endonetics Inc.